Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: A cost-effectiveness analysis

Circulation

Volumn 125, Issue 2, 2012, Pages 260-270

  Galper, Benjamin Z ^a   Moran, Andrew ^b   Coxson, Pamela G ^d   Pletcher, Mark J ^d   Heidenreich, Paul ^e   Lazar, Lawrence D ^f   Rodondi, Nicolas ^g   Wang, Y Claire ^c   Goldman, Lee ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Columbia University Medsical Center ^*  (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

^h College of Physicians and Surgeons ^*  (United States)

Author keywords

cost effectiveness; lipids; prevention; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; COMPUTER SIMULATION; CORONARY DISEASE; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEALTH CARE COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT;

EID: 84862950130     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.041293     Document Type: Article

References (50)

1. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: Comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009 6 e1000058.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
3. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: Data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation. 2007;115:1363-1370. (Pubitemid 46648371)
4. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 150:396-404.
5. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
6. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and costeffectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-254.
7. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost- effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146-53.
8. Balady GJ, Larson MG, Vasan RS, Leip EP, O'Donnell CJ, Levy D. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation. 2004;110:1920-1925. (Pubitemid 39331902)
9. Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation. 2005;112:1566-1572. (Pubitemid 41324517)
10. van Kempen BJ, Spronk S, Koller MT, Elias-Smale SE, Fleischmann KE, Ikram MA, Krestin GP, Hofman A, Witteman JC, Hunink MG. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol. 2011;58:1690-1701.
11. Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker LC. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation. 1996; 93:915-923. (Pubitemid 26074828)
12. Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff MJ. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis. 2006;185:394-399.
13. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: A cross-national study. JAMA. 1998;279:1458-1462. (Pubitemid 28228203)
14. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417-1426. (Pubitemid 18011588)
15. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362:590-599.
16. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346: 1800-1806. (Pubitemid 34586917)
17. National Health and Nutrition Examination Survey 2008. Hyattsville, MD: Centers for Disease Control and Prevention; 2008. http:// www.cdc.gov/nchs/ nhanes.htm. Accessed March 28, 2011.
18. National Health Interview Survey, 2000. Hyattsville, MD: Centers for Disease Control and Prevention; 2000. ftp://ftp.cdc.gov/pub/Health-Statistics/ NCHS/Datasets/NHIS/2000/. Accessed March 28, 2011.
19. National Hospital Discharge Survey 2006. Hyattsville, MD: Centers for Disease Control and Prevention; 2006. http://www.cdc.gov/nchs/about/ major/hdasd/nhds.htm. Accessed March 28, 2011.
20. Framingham Heart Study [CD-ROM]. Department of Health and Human Services. Bethesda, MD: 2005.
21. Personal Health Care Spending by Type of Spending, Age Group, and Source of Payment Distribution, Calendar Year 1999. Baltimore, MD: Centers for Medicare and Medicaid Services; 2000. http://www.cms.hhs. gov/NationalHealthExpendData/ downloads/agAppendix Tables.pdf Accessed March 28, 2011.
22. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. (Pubitemid 23113445)
23. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390. (Pubitemid 34493201)
24. 2009 National Physician Fee Schedule. Center for Medicare and Medicaid Services. https://www.cms.gov/PhysicianFeeSched/PFSRVF/ list.asp. Accessed March 28, 2011.
25. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Health Risks from Exposure to Low Levels of Ionizing Radiation Bier VII Phase 2 Report. National Academy of Sciences, Washington, DC: National Academies Press; 2005. http:// www.nap.edu/openbook.php?isbn-030909156X. Accessed March 28, 2011.
26. Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging: A science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation. 2009;119:1056-1065.
27. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:IV-104 -IV-117.
28. 2010 Red Book: Pharmacy's Fundamental Reference. 114th ed. Montvale, NJ: Thompson Reuters; 2010.
29. The Relative-Based Resource Value Scale. Chicago, IL: American Medical Association; 2006. http://www.ama-assn.org/ama/pub/category/ 16391.html. Accessed October 12, 2008.
30. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849-1860.
31. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706. (Pubitemid 40216039)
32. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med. 2006;144:326-336. (Pubitemid 46768187)
33. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: A cost-utility analysis. Arch Intern Med. 2007;167:290-295.
34. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol. 2006;97:52C-60C.
35. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717-722. (Pubitemid 29401332)
36. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
37. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208-211. (Pubitemid 26057169)
38. Deambrosis P, Terrazzani G, Walley T, Bader G, Giusti P, Debetto P, Chinellato A. Benefit of statins in daily practice? A six-year retrospective observational study. Pharmacol Res. 2009;60:397-401.
39. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. Lancet. 2005;366: 1267-1278.
40. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomized trials of statins: A meta-analysis. Lancet. 2008;371:117-125.
41. Mahenthiran J, Bangalore S, Yao SS, Chaudhry FA. Comparison of prognostic value of stress echocardiography versus stress electrocardiography in patients with suspected coronary artery disease. Am J Cardiol. 2005;96:628-634. (Pubitemid 41207301)
42. Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in coronary revascularization in the United States from 2001 to 2009: Recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes. 2011;4:193-197.
43. Erne P, Schoenenberger A, Zuber M, Burckhardt D, Kiowski W, Dubach P, Resink T, Pfisterer M. Effects of anti-ischemic drug therapy in silent myocardial ischemia type I: The Swiss Interventional Study on Silent Ischemia type I (SWISSI I): A randomized, controlled pilot study. Eur Heart J. 2007;28:2110-2117. (Pubitemid 47517446)
44. Pepine PJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, Miller E, Marks RG, Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: The Atenolol Silent Ischemia Study (ASIST). Circulation. 1994;90:762-768. (Pubitemid 24242742)
45. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial. JAMA. 2009;301:1547-1555.
46. Chou R, Arora B, Dana T, Fu R, Walker M, Humphery L. Screening asymptomatic adults with resting or exercise electrocardiography: A review of the evidence for the US Preventive Services Task Force. Ann Int Med. 2011;155:375-385.
47. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25:445-451. (Pubitemid 32055602)
48. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010:3: CD004371.
49. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD, Winters WL Jr, Yanowitz FG, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA guidelines for exercise testing: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation. 1997;96:345-354. (Pubitemid 27298443)
50. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92-97.